Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of rivastigmine for Alzheimer's dementia
ChiCTR2100048964Phase 4Recruiting
- Sponsor
- Yuanxin Technology
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivastigmine in Alzheimer's disease (AD), sponsored by Yuanxin Technology. Primary endpoints: Dementia score (CDR) decline rate after 24 weeks of treatment, Functional activity questionnaire scoring and 1 more. Started May 2021; status: recruiting.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2100048964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048964.